ZURICH: Roche Holding mentioned its Tecentriq drug mixed with platinum-based chemotherapy diminished the chance of the illness worsening or demise in sufferers with superior bladder most cancers, the Swiss pharma firm mentioned on Monday.
Tecentriq was the primary most cancers immunotherapy permitted in bladder most cancers, with Roche now evaluating the therapy together with different medicines for early and superior types of the illness.
The Part III examine met its targets of stopping the situation worsening, in comparison with chemotherapy alone. Roche mentioned it might share the info with the U.S. Meals and Drug Administration and the European Medicines Company.